

# Darrell J Yamashiro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2993607/publications.pdf>

Version: 2024-02-01

86  
papers

4,343  
citations

126907

33  
h-index

106344

65  
g-index

88  
all docs

88  
docs citations

88  
times ranked

5129  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel CD63-PRKCB fusion in a case of pigmented epithelioid melanocytoma. <i>Pediatric Dermatology</i> , 2022, 39, 322-323.	0.9	2
2	Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma. <i>Pediatric Transplantation</i> , 2022, 26, e14209.	1.0	11
3	High-Dose Radiation Increases Notch1 in Tumor Vasculature. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 857-866.	0.8	10
4	4304 Immune markers in tumor immune microenvironment of neuroblastoma correlate with risk groups. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 136-136.	0.6	0
5	Malignant Rhabdoid Tumor, an Aggressive Tumor Often Misclassified as Small Cell Variant of Hepatoblastoma. <i>Cancers</i> , 2019, 11, 1992.	3.7	16
6	Disseminated trichosporonosis with atypical histologic findings in a patient with acute lymphocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 159-161.	1.3	8
7	INI1 negative hepatoblastoma, a vanishing entity representing malignant rhabdoid tumor. <i>Human Pathology: Case Reports</i> , 2018, 12, 42-47.	0.2	2
8	Notch1 Signaling in Neuroblastoma Tumor Vasculature after High-Dose Radiation Therapy. <i>Journal of the American College of Surgeons</i> , 2018, 227, S198.	0.5	0
9	Erythema nodosum arising during everolimus therapy for tuberous sclerosis complex. <i>Pediatric Dermatology</i> , 2018, 35, e235-e236.	0.9	6
10	Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. <i>Oncogene</i> , 2018, 37, 5451-5465.	5.9	22
11	A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome—Review of the Literature. <i>Frontiers in Pediatrics</i> , 2017, 5, 114.	1.9	8
12	Abstract 702: A novel cell-penetrating ATF5 antagonist peptide CP-d/n-ATF5 exerts in vitro and in vivo anti-tumor effects in a broad spectrum of pediatric cancers. , 2017, , .		1
13	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. <i>Genome Medicine</i> , 2016, 8, 133.	8.2	147
14	HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. <i>Nature Medicine</i> , 2016, 22, 1180-1186.	30.7	158
15	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. <i>Genome Medicine</i> , 2016, 8, 116.	8.2	15
16	High-Dose, Single-Fraction Irradiation Rapidly Reduces Tumor Vasculature and Perfusion in a Xenograft Model of Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1173-1180.	0.8	28
17	Abstract A27: INI1 negative hepatoblastoma, a vanishing entity representing malignant rhabdoid tumor. , 2016, , .		0
18	Notch Suppresses Angiogenesis and Progression of Hepatic Metastases. <i>Cancer Research</i> , 2015, 75, 1592-1602.	0.9	45

#	ARTICLE	IF	CITATIONS
19	Abstract 1946: Activating transcription factor 5 (ATF5) in highly expressed in Stage 4, MYCN-amplified neuroblastoma. , 2015, , .		1
20	Abstract 2083: TFAP4 inhibits differentiation of MYCN-amplified neuroblastoma. , 2015, , .		0
21	Inhibition of notch promotes liver metastasis. Aging, 2015, 7, 603-604.	3.1	1
22	Correlation of tumor-associated macrophages and clinicopathological factors in Wilms tumor. Vascular Cell, 2013, 5, 5.	0.2	16
23	Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis. Vascular Cell, 2013, 5, 17.	0.2	31
24	A screen for inducers of p21waf1/cip1 identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. Neurobiology of Disease, 2013, 49, 13-21.	4.4	23
25	Polyplex-microbubbles for ultrasound-mediated gene therapy. Proceedings of Meetings on Acoustics, 2013, , .	0.3	4
26	Monitoring early tumor response to drug therapy with diffuse optical tomography. Journal of Biomedical Optics, 2012, 17, 016014.	2.6	23
27	Inhibition of host Notch function disrupts hepatic vasculature, and promotes tumor growth. Journal of the American College of Surgeons, 2012, 215, S70-S71.	0.5	0
28	Contrast Ultrasound Imaging for Identification of Early Responder Tumor Models to Anti-Angiogenic Therapy. Ultrasound in Medicine and Biology, 2012, 38, 1019-1029.	1.5	53
29	Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors. Journal of Controlled Release, 2012, 157, 224-234.	9.9	112
30	Abstract 2325: Increase in neuroblastoma metastasis after dual inhibition of VEGF and Notch. , 2012, , .		0
31	A Common Symptom of an Uncommon Disease. Journal of Pediatric Hematology/Oncology, 2011, 33, 390-391.	0.6	2
32	Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor. Vascular Cell, 2011, 3, 22.	0.2	10
33	Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors. Oncologist, 2011, 16, 1614-1625.	3.7	23
34	Transport-theory based multispectral imaging with PDE-constrained optimization. , 2011, , .		1
35	Optical tomographic monitoring of vascular responses to anti-angiogenic drugs in preclinical tumor models. , 2011, , .		0
36	PDE-constrained multispectral imaging of tissue chromophores with the equation of radiative transfer. Biomedical Optics Express, 2010, 1, 812.	2.9	65

#	ARTICLE	IF	CITATIONS
37	Comparing tumor response to VEGF blockade therapy using high frequency ultrasound imaging with size-selected microbubble contrast agents. , 2010, , .		0
38	Monitoring of anti-angiogenic drug response with dynamic fluorescence imaging. , 2010, , .		2
39	Early Detection of Tumor Vascular Response to Anti-Angiogenic Drugs with Optical Tomography. , 2010, , .		1
40	Dynamic Fluorescence Imaging For The Detection of Vascular Changes in Anti-Angiogenic Drug Therapy. , 2010, , .		2
41	Angiogenesis in Tumour Development and Metastasis. , 2010, , 81-93.		0
42	Abstract 1282: Notch and VEGF regulate tumor endothelial cell survival. , 2010, , .		0
43	The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review. Pediatric Radiology, 2009, 39, 723-726.	2.0	40
44	Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatric Blood and Cancer, 2009, 52, 669-671.	1.5	25
45	Vascular characterization of clear cell sarcoma of the kidney in a child: a case report and review. Journal of Pediatric Surgery, 2009, 44, 2031-2036.	1.6	15
46	Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. International Journal of Oncology, 2009, 34, 401-7.	3.3	14
47	A Notch1 Ectodomain Construct Inhibits Endothelial Notch Signaling, Tumor Growth, and Angiogenesis. Cancer Research, 2008, 68, 4727-4735.	0.9	147
48	Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 399-405.	1.6	240
49	Optical Tomographic Imaging of Tumor Hemodynamics during Anti-VEGF Treatment in Mice. , 2006, , .		0
50	Genomic Profiling Maps Loss of Heterozygosity and Defines the Timing and Stage Dependence of Epigenetic and Genetic Events in Wilms' Tumors. Molecular Cancer Research, 2005, 3, 493-502.	3.4	62
51	Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. International Journal of Oncology, 2004, 25, 549.	3.3	14
52	Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resistance Updates, 2004, 7, 289-300.	14.4	82
53	Biomolecular markers and involution of hemangiomas. Journal of Pediatric Surgery, 2004, 39, 400-404.	1.6	49
54	TNP-470 promotes initial vascular sprouting in xenograft tumors. Molecular Cancer Therapeutics, 2004, 3, 335-43.	4.1	22

#	ARTICLE	IF	CITATIONS
55	Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis. <i>Molecular Cancer Research</i> , 2004, 2, 36-42.	3.4	90
56	Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms's tumor. <i>Journal of Pediatric Surgery</i> , 2003, 38, 1569-1573.	1.6	25
57	Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis. <i>Journal of Pediatric Surgery</i> , 2003, 38, 308-314.	1.6	32
58	Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7785-7790.	7.1	234
59	VEGF blocking therapy in the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 263-276.	3.1	159
60	Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. <i>International Journal of Oncology</i> , 2003, 23, 1651.	3.3	9
61	VEGF blocking therapy in the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 263-276.	3.1	1
62	Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11399-11404.	7.1	305
63	Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. <i>Journal of Pediatric Surgery</i> , 2002, 37, 518-522.	1.6	41
64	P53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease. <i>Journal of Pediatric Surgery</i> , 2002, 37, 523-527.	1.6	19
65	Resistance of a VEGF-producing tumor to anti-VEGF antibody: Unimpeded growth of human rhabdoid tumor xenografts. <i>Journal of Pediatric Surgery</i> , 2002, 37, 528-532.	1.6	7
66	Topotecan is anti-angiogenic in experimental hepatoblastoma. <i>Journal of Pediatric Surgery</i> , 2002, 37, 857-861.	1.6	26
67	Chromosome arm 16q in Wilms tumors: Unbalanced chromosomal translocations, loss of heterozygosity, and assessment of theCTCF gene. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 156-163.	2.8	40
68	All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2001, 36, 287-290.	1.6	37
69	Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. <i>Journal of Pediatric Surgery</i> , 2001, 36, 357-361.	1.6	65
70	Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2001, 36, 1177-1181.	1.6	61
71	Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. <i>Journal of Pediatric Surgery</i> , 2001, 36, 1781-1784.	1.6	35
72	Suppression of primary tumor growth in a mouse model of human neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2000, 35, 977-981.	1.6	41

#	ARTICLE	IF	CITATIONS
73	Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. <i>Journal of Pediatric Surgery</i> , 2000, 35, 30-33.	1.6	115
74	Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting. <i>Human Molecular Genetics</i> , 1999, 8, 1337-1352.	2.9	64
75	Biology and Genetics of Human Neuroblastomas. <i>The American Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 93-101.	1.3	205
76	Biology and Genetics of Human Neuroblastomas. <i>Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 93-101.	0.6	7
77	Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/Velo-cardio-facial chromosomal region in 22q11.2. <i>Human Molecular Genetics</i> , 1995, 4, 763-766.	2.9	144
78	Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). <i>Genomics</i> , 1995, 25, 538-546.	2.9	88
79	Kinetics of $\beta$ 2-macroglobulin endocytosis and degradation in mutant and wild-type Chinese hamster ovary cells. <i>Journal of Cellular Physiology</i> , 1989, 139, 377-382.	4.1	39
80	Regulation of endocytic processes by pH. <i>Trends in Pharmacological Sciences</i> , 1988, 9, 190-193.	8.7	52
81	Endosome Acidification and the Pathways of Receptor-Mediated Endocytosis. <i>Advances in Experimental Medicine and Biology</i> , 1987, 225, 189-198.	1.6	99
82	Acidification of endocytic compartments and the intracellular pathways of ligands and receptors. <i>Journal of Cellular Biochemistry</i> , 1984, 26, 231-246.	2.6	125
83	Segregation of transferrin to a mildly acidic (pH 6.5) para-golgi compartment in the recycling pathway. <i>Cell</i> , 1984, 37, 789-800.	28.9	566
84	ACIDIFICATION OF ENDOCYTIC VESICLES AND THE INTRACELLULAR PATHWAYS OF LIGANDS AND RECEPTORS. <i>Annals of the New York Academy of Sciences</i> , 1983, 421, 424-433.	3.8	21
85	Structure-Activity Relationships of Somatostatin Analogs in the Rabbit Ileum and the Rat Colon. <i>Journal of Clinical Investigation</i> , 1983, 71, 840-849.	8.2	28
86	Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. <i>Oncology Reports</i> , 0, , .	2.6	4